2 June 2025

Stability Testing Commences for New Oral Products to Treat Erectile Dysfunction and Dysmenorrhea

Key Milestone Achieved Towards Regulatory Approval of Lead Products

- Stability testing now underway for new oral products to treat erectile dysfunction and provide dysmenorrhea relief
- Required step in Australian regulatory submission process
- Submissions on track for mid-2025, with approvals expected before year-end
- Reinforces momentum and alignment with EVE's regulatory and commercial timelines

EVE Health Group (ASX:EVE, EVE or the **Company**), is pleased to announce that stability testing has commenced for its lead products for the treatment of erectile dysfunction (ED) and dysmenorrhoea, a condition characterised by painful menstrual cramps. These oral formulations, developed by Nextract Pty Ltd (**Nextract)**, are based on proven active pharmaceutical ingredients delivered in novel dissolvable formats designed for improved patient experience and faster onset of action.

Stability testing is a mandatory requirement under pharmaceutical product research and development guidelines and provides critical data on product shelf life and integrity under various environmental conditions. The results will form a core component of the technical dossier submitted to the Therapeutic Goods Administration (**TGA**).

This milestone is in line with EVE's regulatory plan to submit both products for TGA review in the coming months. The Company anticipates that approvals will be received before the end of calendar year 2025.

The men's and women's health products are targeting high value, under-served markets, where there is unmet clinical need. Regulatory submissions will leverage Australia's regulatory pathways, which are designed to accelerate access for prescription medicines containing established active ingredients.

EVE TGA Registration Completed

EVE advises that it has completed registration with the TGA as both a registered sponsor and registered manufacturer. This registration allows EVE to progress regulatory applications through the TGA system. The Company views this as a key step in advancing its health and wellness strategy across regulated markets.

Commenting on the milestone, EVE Chief Operating Officer Ben Rohr said:
"Commencing stability testing marks an important step in preparing new medicines for erectile dysfunction and dysmenorrhoea for commercialisation. It reflects the significant technical progress made by the team and keeps us firmly on schedule. We are focused on delivering new therapeutic options where existing solutions are either slow-acting or poorly tolerated."

Nextract Acquisition

EVE executed a binding Share Purchase Deed to acquire 100% of Nextract, an Australian biotech company developing dissolvable oral treatments for regulated pharmaceutical markets on 4 April 2025. Shareholders approved the acquisition on 29 May 2025, with completion expected on or around 12 June 2025.

Authorised for release by Bill Fry, Managing Director.

— ENDS —

For more information, please contact:

Company enquiries
Bill Fry, Managing Director & CEO
EVE Health Group Ltd
+61 8 6465 5500
billf@evehealthgroup.com.au

About EVE Health Group
EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract which is being acquired, EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements regarding the Company's intentions and future business, including the future business of its subsidiaries. These statements reflect current information, expectations, intentions and strategies regarding the future, and are subject to certain risks and uncertainties. Should one or more of these risks or uncertainties materialise, or should any of the underlying assumptions prove incorrect, actual results may vary from the expectations, intentions and strategies described in this presentation.

Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Other than where required by law, the Company is under no obligation to revise any forward-looking statement to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.

All product-related statements in this presentation reflect formulation design intent, or anecdotal user-reported outcomes from early-stage evaluations. These statements are not intended to imply proven clinical efficacy or therapeutic equivalence to existing products. Clinical trials and regulatory assessments are ongoing or pending, and outcomes are subject to change. Investors should not rely on forward-looking statements as guarantees of future performance.